Xiaocheng Li-Sucholeiki

Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer

Jhanelle E. Gray, Isamu Okamoto, Virote Sriuranpong et al. · Clinical Cancer Research · 2019 · 126 citations · Full text

Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD)

Helena A. Yu, Sarah B. Goldberg, Xiuning Le et al. · Clinical Lung Cancer · 2021 · 65 citations · Full text

Oncology, Medicine, Metronomic Therapy +11

SAVANNAH: A Phase II trial of osimertinib plus savolitinib for patients (pts) with <i>EGFR</i>-mutant, <i>MET</i>-driven (<i>MET</i>+), locally advanced or metastatic non-small cell lung cancer (NSCLC), following disease progression on osimertinib.

Geoffrey R. Oxnard, Mireille Cantarini, Paul Frewer et al. · Journal of Clinical Oncology · 2019 · 36 citations

Central Fish, Disease Progression, Pathology +19

Analysis of mutational spectra by denaturing capillary electrophoresis

Per Olaf Ekstrøm, Konstantin Khrapko, Xiaocheng Li-Sucholeiki et al. · Nature Protocols · 2008 · 31 citations · Full text

Engineering, Capillary Electrophoresis, Medicine +8

Clustering of mutant mitochondrial DNA copies suggests stem cells are common in human bronchial epithelium

Hilary A. Coller, Konstantin Khrapko, Pablo Herrero-Jimenez et al. · Mutation research. Fundamental and molecular mechanisms of mutagenesis · 2005 · 19 citations

Human Cell, Cell Lineage, Mitochondrial Biogenesis +7